Guardant Health

Today we announced that the first patient has been enrolled in the National Cancer Institute (NCI)’s Vanguard Study, evaluating our Shield™ multi-cancer detection (MCD) test. The four-year study aims to enroll 24,000 participants and will assess the feasibility of using blood-based tests like Shield to detect multiple cancers in individuals without symptoms—helping shape the future of large-scale cancer screening trials. “New screening technology like the Shield MCD test has the potential to detect multiple cancers earlier through a simple blood draw,” added our Chief Medical Officer, Craig Eagle, MD. “The earlier we can screen and diagnose cancers, the more options we can bring to patients and ultimately the more lives we can save. The Vanguard Study is a critical step in research to evaluate the role of this breakthrough technology in helping reduce cancer deaths.”

Our precision oncology tests are now integrated into the VieCure Halo Intelligence platform, giving oncologists streamlined access to critical insights and enabling community oncology practices to make faster, more personalized treatment decisions for their patients—without complicating existing workflows.   More from Inside Precision Medicine: https://lnkd.in/g8xC6DNm

We're excited to welcome Guardant Health to the VieCure ecosystem! Through this new integration, clinicians can now order and receive Guardant’s next-generation sequencing (NGS)-based precision oncology tests, including Guardant360® Liquid, Guardant360 CDx, Guardant360 Tissue, and Guardant Reveal™, directly within the VieCure Halo Intelligence platform. This partnership simplifies access to genomic insights, streamlines workflows, and brings us one step closer to making precision oncology practical and accessible for every provider, in every setting. Read the full release: https://lnkd.in/gb6xm2UP

Join us for a live webinar on the power of epigenomic biomarkers to improve patient selection and better predict treatment response in oncology clinical trials. While genomic alterations provide critical insight into tumor biology, they often don’t tell the full story. Epigenetic changes, including DNA methylation, provide an additional layer of information that can uncover novel biomarkers, improve deletion detection, and refine cancer subtyping. Panelists Jacob Berchuck, Brad Sickler, Sumit Kar, PhD, and our Senior VP of Clinical Development, Matthew Ellis, will review recent data from AACR and ASCO 2025 and explore how methylation analysis through Guardant Infinity™ can help drive more effective cancer therapies.   Register today: https://lnkd.in/gTAr_yYk 📅 Date: July 24 🕘 Time: 9:00am PT

As our Screening Sales team continues to expand across the U.S., we have a few remaining opportunities for Account Executives and Associate Account Executives to help drive our mission to transform cancer screening by bringing Shield™, our blood-based colorectal cancer screening test, to more patients and providers. If you're a sales professional seeking MORE—more impact, more reward, more purpose—explore our open roles and apply today! #CancerScreening #SalesCareers #OurMissionTheirFuture

Last week, our co-CEO AmirAli Talasaz took the stage at #AspenIdeasHealth on the New Frontiers in Cancer panel, a timely discussion on how breakthroughs in blood-based screening, precision medicine, and AI are reshaping the future of care. From expanding access to early detection to rethinking how we reach underserved communities, the conversation spotlighted what’s possible when innovation meets impact. Watch the full session: https://lnkd.in/eW4mfehW Photo credit: Leigh Vogel

At #AspenIdeasHealth, our co-CEO AmirAli Talasaz sat down with Dr. John Torres to discuss a critical gap in cancer care: screening technologies are advancing, but access isn’t keeping pace. Our FDA-approved Shield™ blood test has the potential to expand access to early detection for millions of people, but outdated policies and uneven coverage still stand in the way. Updating the current guidelines will mean screening and early cancer diagnosis becomes a right and not just a privilege.

There’s no shortage of bold ideas and inspiring conversations this week at #AspenIdeasHealth, a powerful reminder of what’s possible when innovation and access go hand in hand. Today, our co-CEO AmirAli Talasaz is speaking on the New Frontiers in Cancer panel alongside Rodney Gillespie, Alexander Marson, and Elizabeth Cohen to explore how advances like blood-based screening, precision medicine, and AI are changing the future of care. Colorectal cancer screening is a clear example. Despite existing options, millions remain unscreened, particularly in underserved and rural communities. Expanding access to easy-to-use screening options like our Shield™ blood test can help close these persistent gaps and detect cancer earlier. We’re looking forward to the conversation and to driving forward ideas that turn progress into impact.

We are excited to share that our Shield™ blood test for #ColorectalCancer screening has been recognized on Fast Company's 2025 World Changing Ideas list! This recognition showcases the power of innovation to drive meaningful change and improve lives, and we’re honored to be among these remarkable ideas shaping a better world. More details: https://lnkd.in/exdnDePq Explore the full #FCWorldChangingIdeas list: https://lnkd.in/eZQEnfTQ

Today, we’re proud to share that ESMO Open has published results from the LIBERATE study, highlighting Guardant Reveal’s performance in detecting minimal residual disease in early-stage breast cancer. The study reinforces the critical role Reveal can play in clinical decision-making, demonstrating high sensitivity and a 100% positive predictive value for relapse, all without requiring a tissue sample.